Associate Professor, Principal Investigator
Structural guided drug discovery of rare diseases
Structural biology at the crossroad of genetic diseases and drug discovery
Wyatt Yue is a structural biologist with an MA (Biochemistry) from University of Oxford, and a PhD (Crystallography) from Birkbeck College, University of London. He specializes in the use of structural, biochemical and chemical biology approaches to study diverse metabolic protein families in the human genome, with the aim of deciphering the molecular mechanism of human inherited diseases at the protein level.
He leads the ‘Metabolism & Organelle Biogenesis (MOB)’ group at the Centre of Medicines Discovery, Nuffield Department of Medicine. His team has to date deposited >200 human crystals structures in the Protein Data Bank (PDB). Through collaborations with clinicians and pharma partners, his team aims to translate basic science into design of small molecule therapeutics for rare diseases with unmet need.
Current areas of focus include: multiprotein complex machines, glycogen synthesis, vitamin B12 metabolism and Leloir pathway of galactose metabolism.
Defining substrate selection by rhinoviral 2A proteinase through its crystal structure with the inhibitor zVAM.fmk.
Deutschmann-Olek KM. et al, (2021), Virology, 562, 128 - 141
Fragment Screening Reveals Starting Points for Rational Design of Galactokinase 1 Inhibitors to Treat Classic Galactosemia.
Mackinnon SR. et al, (2021), ACS Chem Biol, 16, 586 - 595
Structural biochemistry coming of age in the study of genetic metabolic disorders.
Yue WW., (2021), Biochimie, 183, 1 - 2
Succinyl-CoA:3-oxoacid coenzyme A transferase (SCOT) deficiency: A rare and potentially fatal metabolic disease.
Grünert SC. et al, (2021), Biochimie, 183, 55 - 62
Early-infantile onset epilepsy and developmental delay caused by bi-allelic GAD1 variants.
Neuray C. et al, (2020), Brain, 143, 2388 - 2397